Stockscreener 앱 받기
4.61
2.95%
-0.14
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Published on: 2025-08-21 02:56:29 - newsyoung.net
Vanda says court ruling opens door for Hetlioz jet lag indication - MSN
Technical analysis overview for Vanda Pharmaceuticals Inc. stockWeekly Stock Recap & Real-Time Market Sentiment Alerts - Newser
Is Vanda Pharmaceuticals Inc. reversing from oversold territory2025 Big Picture & Real-Time Volume Surge Alerts - Newser
What indicators show strength in Vanda Pharmaceuticals Inc.Quarterly Risk Review & Free Expert Verified Stock Movement Alerts - Newser
Understanding Vanda Pharmaceuticals Inc.’s price movementJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - Newser
Multi asset correlation models including Vanda Pharmaceuticals Inc.2025 Institutional Moves & Community Consensus Picks - Newser
Vanda Pharmaceuticals' Regulatory Breakthrough: A New Dawn for Hetlioz and Investor Confidence - AInvest
Vanda Pharmaceuticals gets big win in court against FDA for sleep disorder drug - The Business Journals
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark - Stocktwits
Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability - TipRanks
In a major win for Vanda, a federal appeals court overturns FDA's order denying approval of Hetlioz for the treatment of jet lag disorder - MarketScreener
Vanda Pharmaceuticals Secures Victory Over FDA in Jet Lag Disorder Treatment Dispute - AInvest
Vanda Pharmaceuticals shares rise after court overturns FDA denial By Investing.com - Investing.com Canada
Regulatory Reckoning: How Vanda's Legal Victory Reshapes Biopharma's Risk-Reward Landscape - AInvest
Vanda Pharmaceuticals wins court battle against FDA over jet lag drug - Investing.com
Vanda Pharmaceuticals shares rise 5.05% premarket after winning a landmark victory over the FDA. - AInvest
Federal Court Overturns FDA: Vanda's Jet Lag Drug Hetlioz Shows 'Significant Improvement' in Trials - Stock Titan
Can Vanda Pharmaceuticals Inc. benefit from deglobalizationTrade Ideas & Real-Time Stock Movement Alerts - sundaytimes.kr
Comparing Vanda Pharmaceuticals Inc. in custom built stock radars2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Technical signs of recovery in Vanda Pharmaceuticals Inc.2025 Market Overview & Daily Risk Controlled Trade Plans - Newser
Can swing trading help recover from Vanda Pharmaceuticals Inc. losses2025 Big Picture & Capital Efficiency Focused Ideas - Newser
Reversal indicators forming on Vanda Pharmaceuticals Inc. stockDay Trade & Expert Approved Trade Ideas - Newser
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - Newser
Can volume confirm reversal in Vanda Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - Newser
What makes Vanda Pharmaceuticals Inc. stock price move sharplyJuly 2025 Setups & Daily Profit Maximizing Tips - thegnnews.com
Sentiment analysis tools applied to Vanda Pharmaceuticals Inc.July 2025 Breakouts & Free Reliable Trade Execution Plans - Newser
Leading vs lagging indicators on Vanda Pharmaceuticals Inc. performancePortfolio Value Summary & Consistent Profit Trading Strategies - Newser
Will a bounce in Vanda Pharmaceuticals Inc. offer an exitJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
What moving averages say about Vanda Pharmaceuticals Inc.Dividend Hike & Daily Chart Pattern Signal Reports - Newser
Is Vanda Pharmaceuticals Inc. stock poised for growthJuly 2025 Decliners & Accurate Technical Buy Alerts - Newser
Vanda’s Jet Lag Drug Gets Fresh FDA Look After Court Ruling (1) - Bloomberg Law News
Vanda Pharmaceuticals Receives Strong Buy Rating Amidst Growth in Key Product Lines and Promising FDA Decision on Bysanti - AInvest
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
Vanda Pharmaceuticals CEO Buys 10,000 Shares at $4.15/Share on August 7, 2023. - AInvest
Vanda (VNDA) Q2 Revenue Rises 4% - AOL.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Cut to Strong Sell at Wall Street Zen - Defense World
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - Jammu Links News
What is the dividend policy of Vanda Pharmaceuticals Inc. stockSuperior returns - Jammu Links News
Is Vanda Pharmaceuticals Inc. stock overvalued or undervaluedCapitalize on emerging growth stocks - Jammu Links News
What are Vanda Pharmaceuticals Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What institutional investors are buying Vanda Pharmaceuticals Inc. stockRapid growth trajectories - Jammu Links News
What catalysts could drive Vanda Pharmaceuticals Inc. stock higher in 2025Unlock your portfolio’s full growth potential - Jammu Links News
Why is Vanda Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize portfolio value with timely trades - Jammu Links News
What are the technical indicators suggesting about Vanda Pharmaceuticals Inc.Maximize your portfolio’s earning power - Jammu Links News
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with massive upside potential - Jammu Links News
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Phenomenal wealth increase - Jammu Links News
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Get professional advice for market timing - Jammu Links News
Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 502% - AInvest
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses - GuruFocus
1.38%
0.27%
자본화:
|
볼륨(24시간):